Dirk Thye‚ M.D.
Sr. Vice President‚ Drug Development

Dirk Thye is the Sr. Vice President of Drug Development at Cerexa. Dr. Thye has extensive experience in anti–infective research and clinical development in both domestic and international markets. Prior to joining Cerexa‚ Dr. Thye was a founder and Sr. Vice President of Clinical Development at Peninsula Pharmaceuticals where he was responsible for the clinical development of Peninsula’s anti–infective portfolio. Prior to founding Peninsula‚ Dr. Thye led the clinical development program at Vicuron Pharmaceuticals for anidulafungin‚ a systemic antifungal compound which has been approved for commercial use and was subsequently acquired by Pfizer in 2005. Dr. Thye is board certified in Internal Medicine and graduated with honors from UCLA School of Medicine. He completed his post–graduate training in Internal Medicine at the Stanford University Medical Center. Dr. Thye also holds a Bachelor of Arts degree in Molecular Biology from the University of California at Berkeley.

Rick Orr‚ J.D.
Sr. Vice President, Operations

Rick Orr is the Sr. Vice President, Operations at Cerexa. Mr. Orr was part of the management team that founded Cerexa and served as General Counsel until October 2007. Prior to joining Cerexa‚ Mr. Orr was the Associate General Counsel of Peninsula Pharmaceuticals and was instrumental in structuring the spin–out of Cerexa and the acquisition of Peninsula by Johnson & Johnson. Prior to working at Peninsula‚ Mr. Orr was an attorney at Cooley Godward LLP where he was outside counsel for biotechnology and technology clients‚ handling venture financing transactions‚ public offerings‚ mergers and acquisitions‚ strategic corporate relationships‚ SEC reporting and compliance‚ and corporate governance. Mr. Orr received a J.D.‚ magna cum laude‚ from the University of San Francisco School of Law. He received a B.A. from The Ohio State University and an M.A. from the University of California‚ Santa Barbara. Mr. Orr is a member of the State Bar of California.

Ian A. Critchley, Ph.D.
Vice President, Clinical Microbiology

Ian Critchley is the Vice President of Clinical Microbiology at Cerexa. Dr. Critchley joined Cerexa in June 2008 and brings more than 20 years of experience in antibacterial drug discovery and development. Prior to joining Cerexa, Dr. Critchley was Executive Director of Microbiology at Replidyne, where he led a team responsible for all pre-clinical and clinical microbiology studies on antibacterial agents in the development pipeline. Dr. Critchley came to Replidyne from Focus Technologies (now Eurofins Medinet) where he was Director of Laboratory Services and established the microbiology laboratory that provides contract research services to evaluate new agents in IND and NDA-enabling studies and monitors resistance in global surveillance studies. Prior to joining Focus Technologies, Dr. Critchley was a Senior Investigator and Group Leader in Microbiology Research at SmithKline Beecham Pharmaceuticals where he led discovery research groups in both the U.K. and Philadelphia. Dr. Critchley holds a Ph.D. degree in Microbiology obtained from the University of Glasgow, Scotland, U.K. and a B.Sc. (Hons) degree in Microbiology obtained from University College Cardiff, Wales, U.K. Dr. Critchley is a member of the American Society for Microbiology, the U.K. Society for General Microbiology and the British Society for Antimicrobial Chemotherapy.

David Friedland, M.D.
Vice President, Clinical Sciences

David Friedland is the Vice President of Clinical Sciences at Cerexa. Dr. Friedland joined Cerexa in June 2008 and has extensive experience in the field of infectious diseases, encompassing both academia and the pharmaceutical industry. Prior to joining Cerexa, Dr. Friedland was Senior Director of Clinical Research at Theravance from 2005, where he was responsible for the hospital-acquired pneumonia program and a major contributor to the NDA for telavancin, a gram-positive antibacterial agent. Dr. Friedland came to Theravance from Migenix, a biopharmaceutical company in Vancouver, BC developing antibacterial and antiviral agents. Dr. Friedland served in various positions over an 8 year period, most recently as Vice President, Clinical and Medical Affairs. Dr. Friedland obtained his M.D. and Master of Medicine (Microbiology) degree from the University of the Witwatersrand, Johannesburg, South Africa. He also holds a MBA from Queens University, ON, Canada and is a Fellow of the Infectious Diseases Society of America.

Trisha Dobson, M.B.A., P.M.P.
Executive Director, Project Management

Trisha Dobson is the Executive Director of Project Management at Cerexa. Ms. Dobson was part of the team that founded Cerexa and heads the Project Management function. Ms. Dobson has worked in many stages of development throughout her career and currently leads the product team for a key antibiotic product. Prior to Cerexa, Ms. Dobson held positions in Project Management at Peninsula Pharmaceuticals, which was acquired by Johnson & Johnson. Prior to working at Peninsula Pharmaceuticals, Ms. Dobson developed and directed the Project Management department at Cerus, instituting a number of key business and strategic management tools. She has been in the industry for more than 15 years, focusing most recently on Project Management. She has worked in both the pharmaceutical and diagnostic environments, and has held key roles on a number of international projects. Ms. Dobson received a B.S. from Case Western University and holds an M.B.A. from St. Mary’s University. Ms. Dobson is a certified P.M.P., Project Management Professional.

Jon Lee
Executive Director, Clinical Operations

Jon Lee, Executive Director of Clinical Operations, joined Cerexa in June 2006. Mr. Lee served in positions of increasing responsibilities at Nektar Therapeutics/inhale from 1999 until joining Cerexa. Prior to Nektar, he held various positions within Clinical Operations at Gilead Sciences and Genentech Inc. Mr. Lee has developed and managed departments and interdisciplinary project teams in each discipline of drug development in such therapeutic areas as infectious disease, oncology, neurology, and pulmonology. Mr. Lee graduated from the University of Illinois with a B.S. in Chemistry.